Prof. Dr. HAKAN HARPUTLUOĞLU

Yayın Ağı

Makaleler 24

1. Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)

Siefker-Radtke A. O., Huddart R. A., Bilen M. A., Balar A., Castellano D., Sridhar S. S., et al.

Urologic Oncology: Seminars and Original Investigations , cilt.43, sa.5, 2025 (SCI-Expanded, Scopus)

2. Advanced Hepatocellular Cancer Treated with Sorafenib and Novel Inflammatory Markers

Gulmez A., HARPUTLUOĞLU H.

JOURNAL OF GASTROINTESTINAL CANCER , cilt.54, sa.1, ss.11-19, 2023 (ESCI, Scopus) Sürdürülebilir Kalkınma

3. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.

Yildirim M. E., Karaca M., Artac M., Cicin I., Geredeli C., Alacacioglu A., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.16, 2022 (SCI-Expanded, Scopus)

4. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Bilici A., Olmez O. F., Sezer A., Oksuzoglu B., Kaplan M. A., Karadurmus N., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.16, 2022 (SCI-Expanded, Scopus)

5. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Petrylak D. P., de Wit R., Chi K. N., Drakaki A., Sternberg C. N., Nishiyama H., et al.

LANCET ONCOLOGY , cilt.21, sa.1, ss.105-120, 2020 (SCI-Expanded, Scopus)

6. Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma

AKSOY A., Elkiran E. T., Harputluoglu H., Dagli A. F., Isikdogan A., Urakci Z.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.15, sa.3, ss.550-555, 2019 (SCI-Expanded, Scopus)

7. POSTERIOR REVERSIBLE LEUKOENCEPHALOPATHY SYNDROME DEVELOPING SECONDARY TO SUNITINIB THERAPY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA

Kaplan N. B., HARPUTLUOĞLU H., Dikilitas M., ELKIRAN E. T., TEMELLİ Ö.

ACTA MEDICA MEDITERRANEA , cilt.34, sa.1, ss.39-42, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

8. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Petrylak D. P., de Wit R., Chi K. N., Drakaki A., Sternberg C. N., Nishiyama H., et al.

LANCET , cilt.390, sa.10109, ss.2266-2277, 2017 (SCI-Expanded, Scopus)

9. Drug induced autoimmune hepatitis: A Single Center Experience

BİLGİÇ Y., HARPUTLUOĞLU H., YILMAZ C., KARADAĞ N., ÇAĞIN Y. F., AKBULUT A. S., et al.

BİOMEDİCAL RESEARCH-INDİA , cilt.28, sa.15, ss.6528-6532, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma

10. Drug induced autoimmune hepatitis: a single center experience.

Bilgic Y., Harputluoglu H., Yilmaz C., Karadag Soylu N., Cagin Y. F., Akbulut S., et al.

BIOMEDICAL RESEARCH-INDIA , cilt.28, sa.15, ss.6528-6532, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

11. Does the tumor necrosis factor a predictor factor in patients with chronic hepatitis B and C

Bilgic Y., Seckin Y., Cagin Y. F., Yildirim O., Yilmaz C., Harputluoglu M., et al.

BIOMEDICAL RESEARCH-INDIA , cilt.28, sa.4, ss.1683-1688, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Estimation of risk factors associated with colorectal cancer: an application of knowledge discovery in databases

Firat F., ARSLAN A. K., ÇOLAK C., HARPUTLUOĞLU H.

KUWAIT JOURNAL OF SCIENCE , cilt.43, sa.2, ss.151-161, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

13. Factors Affecting Survival in Non-Small Cell Lung Cancer Patients with Brain Metastasis

HARPUTLUOĞLU H., Kaplan N., Dikilitas M., Yagar Y.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.4, ss.199-205, 2016 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

14. Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology

Bilici A., Ozturk T., Turkmen E., Odabas H., Cihan S., Selcukbiricik F., et al.

WORLD JOURNAL OF UROLOGY , cilt.33, sa.10, ss.1613-1622, 2015 (SCI-Expanded, Scopus)

15. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers

Baykara M., BENEKLİ M., Ekinci O., Irkkan S. C., Karaca H., Demirci U., et al.

JOURNAL OF GASTROINTESTINAL SURGERY , cilt.19, sa.9, ss.1565-1571, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

16. Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study

Abali H., ÇELİK İ., Karaca B., TURNA Z. H., Saglam E. K., Akman T., et al.

JOURNAL OF BUON , cilt.20, sa.4, ss.1137-1141, 2015 (SCI-Expanded, Scopus)

17. A rare granular cell tumor of the vulva: a case report

Bozdag Kaplan N., Dursun I. H., Dikilitas M., HARPUTLUOĞLU H., YILMAZ E., Sahin N.

TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.30, sa.2, ss.78-81, 2015 (ESCI, Scopus)

18. Outcome of 561 non-metastatic triple negative breast cancer patients: Multi-center experience from Turkey

Budakoglu B., Altundag K., Aksoy S., Kaplan M. A., Ozdemir N. Y., Berk V., et al.

JOURNAL OF BUON , cilt.19, sa.4, ss.872-878, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

19. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)

Cetin B., BENEKLİ M., Turker I., Koral L., Ulas A., DANE F., et al.

JOURNAL OF CHEMOTHERAPY , cilt.26, sa.5, ss.300-305, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience

KEFELİ U., BENEKLİ M., Sevinc A., Yildiz R., Kaplan M. A., Ciltas A., et al.

ONCOLOGY LETTERS , cilt.6, sa.2, ss.605-611, 2013 (SCI-Expanded, Scopus)

21. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)

Demirci U., Tufan G., Aktas B., Balakan O., ALACACIOĞLU A., DANE F., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.139, sa.5, ss.829-835, 2013 (SCI-Expanded, Scopus)

22. Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients

Uncu D., Aksoy S., Cetin B., Yetisyigit T., Ozdemir N., Berk V., et al.

ONCOLOGY , cilt.84, sa.4, ss.240-245, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

23. Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience

Cetin B., BENEKLİ M., Oksuzoglu B., Koral L., Ulas A., DANE F., et al.

ONKOLOGIE , cilt.35, sa.12, ss.740-745, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

24. Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients

ELKIRAN E. T., Kaplan M. A., Sevinc A., Aksoy S., Demirci U., Seker M., et al.

MEDICAL ONCOLOGY , cilt.29, sa.5, ss.3147-3154, 2012 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 6

1. EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.

Gumus M., Geredeli C., Ucar M., Kaya S., Demir H., Unal O. U., et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri) Sürdürülebilir Kalkınma

2. ESTIMATION OF RISK FACTORS ASSOCIATED WITH COLORECTAL CANCER AN APPLICATION OF KNOWLEDGE DISCOVERY IN DATABASES

FIRAT F., ARSLAN A. K., ÇOLAK C., HARPUTLUOĞLU H.

International Symposium on Econometrics, Operations Research and Statistics, 2 - 04 Haziran 2016, (Özet Bildiri) Sürdürülebilir Kalkınma

3. Breast cancer subtypes and the risk of distant relapse after breast conserving surgery or mastectomy: An Anatolian Society of Medical Oncology study.

Kaplan M. A., Urakci Z., Uncu D., Dane F., Ozkan M., Akman T., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma

4. Results of observational study to determine K-ras mutation rates in 2458 patients with metastatic colorectal cancer in Turkey (TURKRAS Study).

Gumus M., Dane F., Karabulut B., Uygun K., Aydin K., Orhan B., et al.

5. Frequency and risk factors of potential drug interactions in breast cancer patients.

Acar F., Dursun B. H., Harputluoglu H., Yigit A., Kilic M. S., Elkiran E. T.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

6. The effect of front-line chemotherapy on overall survival in patients with malignant pleural mesothelioma.

Elkiran E. T., Sevinc A., Harputluoglu H.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

145

H-İndeks (WoS)

Atıf (Scopus)

167

H-İndeks (Scopus)

Proje

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler